Modality
Small Molecule
MOA
JAK1i
Target
CDK4/6
Pathway
Lipid Met
Wilms
Development Pipeline
Preclinical
~Jul 2012
→ ~Oct 2013
Phase 1
~Jan 2014
→ ~Apr 2015
Phase 2
~Jul 2015
→ ~Oct 2016
Phase 3
Jan 2017
→ Oct 2030
Phase 3Current
NCT07633311
2,077 pts·Wilms
2020-04→2029-03·Recruiting
NCT04202230
1,258 pts·Wilms
2020-01→2030-10·Not yet recruiting
NCT04188134
1,656 pts·Wilms
2017-01→2025-04·Recruiting
+1 more trial
7,167 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-04-0812mo agoPh3 Readout· Wilms
2029-03-122.9y awayPh3 Readout· Wilms
2030-07-244.3y awayPh3 Readout· Wilms
2030-10-084.5y awayPh3 Readout· Wilms
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P3
Recruit…
P3
Not yet…
P3
Recruit…
P3
Complet…
Catalysts
Ph3 Readout
2025-04-08 · 12mo ago
Wilms
Ph3 Readout
2029-03-12 · 2.9y away
Wilms
Ph3 Readout
2030-07-24 · 4.3y away
Wilms
Ph3 Readout
2030-10-08 · 4.5y away
Wilms
RecruitingCompletedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07633311 | Phase 3 | Wilms | Recruiting | 2077 | PANSS |
| NCT04202230 | Phase 3 | Wilms | Not yet recr... | 1258 | SRI-4 |
| NCT04188134 | Phase 3 | Wilms | Recruiting | 1656 | EDSS |
| NCT03812106 | Phase 3 | Wilms | Completed | 2176 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| ROI-1081 | Roivant Sciences | Phase 1/2 | PI3Kα | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 |